Sugi Predict

Sugi Predict / Targets / ESRRA

ESRRA

Steroid hormone receptor ERR1 · P11474 · ESRRA on Sugi Atlas →

29,361 patent compounds predicted against ESRRA, 20,058 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL650140 SCHEMBL650140 1.00 19/20
SCHEMBL650141 SCHEMBL650141 1.00 19/20
SCHEMBL648930 SCHEMBL648930 0.79 17/20
SCHEMBL648931 SCHEMBL648931 0.79 17/20
SCHEMBL648125 SCHEMBL648125 0.63 17/20
SCHEMBL648126 SCHEMBL648126 0.63 17/20
SCHEMBL648909 SCHEMBL648909 0.62 17/20
SCHEMBL648910 SCHEMBL648910 0.62 17/20
SCHEMBL650091 SCHEMBL650091 0.62 17/20
SCHEMBL651256 SCHEMBL651256 0.62 17/20
SCHEMBL650136 SCHEMBL650136 0.62 16/20
SCHEMBL650137 SCHEMBL650137 0.62 16/20
SCHEMBL649119 SCHEMBL649119 0.62 15/20
SCHEMBL649120 SCHEMBL649120 0.62 15/20
SCHEMBL648940 SCHEMBL648940 0.63 13/20
SCHEMBL648941 SCHEMBL648941 0.63 13/20
SCHEMBL648615 SCHEMBL648615 0.62 13/20
SCHEMBL648616 SCHEMBL648616 0.62 13/20
SCHEMBL650131 SCHEMBL650131 0.61 13/20
SCHEMBL650132 SCHEMBL650132 0.61 13/20

Clinical trials — most relevant to ESRRA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women PHASE3COMPLETED
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation PHASE3UNKNOWN
Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring PHASE3COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer PHASE2UNKNOWN
Phase II Study of Single Agent Lenvatinib PHASE2UNKNOWN
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer PHASE2UNKNOWN
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Sexual Hormones and Haemostasis: Observations for Women Health nanUNKNOWN
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? nanUNKNOWN
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer nanCOMPLETED
Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer nanUNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. nanCOMPLETED
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Purinergic Signaling and the Postmenopausal Heart nanRECRUITING
Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 nanCOMPLETED
REFUEL PCOS Study 1 nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ESRRA binder may also engage these)

ProteinNameSimilarity
Q6QMY5 — 1.000 Q6QMY5 →
Q5QJV7 — 1.000 Q5QJV7 →
O08580 — 1.000 O08580 →
NR5A1 Steroidogenic factor 1 0.993 landscape →
P50569 — 0.993 P50569 →
Q95L87 — 0.992 Q95L87 →
P43136 — 0.992 P43136 →
Q9GKL2 — 0.991 Q9GKL2 →
P33242 — 0.991 P33242 →
P10588 — 0.990 P10588 →
O09017 — 0.989 O09017 →
P49870 — 0.989 P49870 →
NR1H2 Oxysterols receptor LXR-beta 0.989 landscape →
Q04752 — 0.989 Q04752 →
RXRB Retinoic acid receptor RXR-beta 0.989 landscape →
P79387 — 0.989 P79387 →
P28704 — 0.987 P28704 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.987 landscape →
Q5TJF7 — 0.986 Q5TJF7 →
O75064 — 0.985 O75064 →
ESRRB Steroid hormone receptor ERR2 0.985 landscape →
Q9QXZ7 — 0.985 Q9QXZ7 →
Q0ZAQ8 — 0.985 Q0ZAQ8 →
NR4A3 Nuclear receptor subfamily 4 group A member 3 0.984 landscape →
P12813 — 0.984 P12813 →
Q5BIS6 — 0.984 Q5BIS6 →
Q7SYN5 — 0.984 Q7SYN5 →
O95475 — 0.984 O95475 →
NR2E1 Nuclear receptor subfamily 2 group E member 1 0.983 landscape →
Q64249 — 0.983 Q64249 →